Technology

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

If used properly, AI can be a game-changer for drug development.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, addresses patient and prescriber expectations for digital health tools.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Experts weigh in on today’s life sciences leadership-development priorities critical to long-term success.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores ways that digital health platforms can assist pharma companies seeking to maintain accessibility and manage cost pressures.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.

James Foster, CEO and co-founder of Virax Biolabs, discusses how AI and machine-learning algorithms are changing the ways that companies approach their launch strategies.

The benefits for brand teams in bolstering their rapid-response capability.

The TileDB CEO discusses how the life sciences can overcome these limitations.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.

Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.

Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.

A Q&A with Harvard’s Laura Wegner, serial entrepreneur and Rhodes Scholar-elect.

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome.

The Upscript Health CEO discusses trends in telehealth for the coming year.

How alternative direct-to-consumer models are changing the landscape for patient access.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.